Loading the records…
Loading the records…
The Aviation Medication Transparency Act of 2025 (H.R. 2592) was ordered to be reported (amended) by voice vote in the House Transportation and Infrastructure Committee on September 15, 2026, and now awaits floor action. The bill mandates the FAA to publish and annually update a public list of medications approved for airmen medical certification, along with 'Do Not Issue' lists and contact mechanisms. It is a transparency-focused administrative mandate with no direct funding or procurement provisions, and no specific public companies are directly implicated. The primary market impact is indirect, affecting aviation safety and healthcare information sectors at a low confidence level.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
The bill's passage would not alter revenue streams or capital requirements for any public company. Airlines and aerospace firms (e.g., Delta Air Lines $DAL, United Airlines $UAL, GE Aerospace $GE) might see negligible operational benefits from reduced pilot certification friction, but the effect is too indirect to justify a trade. Healthcare information companies (e.g., IQVIA $IQV) could theoretically benefit from increased medication data dissemination, but the bill does not mandate any specific technology or service procurement. Investors should treat this as a procedural legislative update with no actionable market signal.
The Aviation Medication Transparency Act of 2025 (H.R. 2592), introduced by Rep. Sean Casten (D-IL) in April 2025, was reported out of the House Transportation and Infrastructure Committee on September 15, 2026, with amendments, and is now awaiting floor action. The bill directs the FAA to compile, publish, and annually update a publicly accessible list of medications that may be safely prescribed to pilots and air traffic controllers for medical certification, along with the existing 'Do Not Issue' and 'Do Not Fly' lists. It also requires a mechanism for medical providers to contact the FAA with questions and includes stakeholder input from air traffic controller bargaining representatives. The bill is a transparency mandate—it does not authorize or appropriate any specific funding amount, and it does not alter FAA regulatory authority beyond publishing existing internal lists. Because the bill is purely administrative and informational, its direct market impact is minimal. No specific public company is named or directly affected by the bill's provisions. The aviation industry, including airlines and aerospace manufacturers, may see indirect benefits from improved clarity in pilot medication rules, potentially reducing pilot certification delays and improving workforce availability, but this is a diffuse effect. The healthcare information sector could see a minor tailwind from increased demand for medication data dissemination, but no pure-play public company is clearly positioned to capture this. The bill's legislative momentum is moderate: it has cleared committee with bipartisan voice vote support, but floor scheduling remains uncertain. Given the procedural nature and lack of direct economic mechanisms, the confidence in any ticker-level impact is low, and the affected sectors are limited to Transportation and Healthcare.
Matched on shared policy language across AI analyses, with ticker & timing weight
Aviation Medication Transparency Act of 2025
FREQUENTIS USA, INC: $125M Department of Transportation Contract
INDRA AIR TRAFFIC, INC.: $386M Department of Transportation Contract
FREQUENTIS USA, INC: $125M Department of Transportation Contract
Executive orders & memoranda affecting the same sectors or companies
This proclamation modifies the list of Canadian products subject to a 50% additional ad valorem duty imposed under Section 338 of the Tariff Act of 1930, removing some products from the duty and adding others, effective October 30, 2026. The action is part of an ongoing dispute over Canada's motor vehicle tariff scheme and is intended to offset discrimination against U.S. commerce. The President directs implementation through the Harmonized Tariff Schedule and authorizes U.S. Customs and Border Protection to issue rules.
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →